Evidence map›Paper›PMID 33278457›Full record

ArticleMicrovascular research2021

Systemic microvascular endothelial dysfunction and disease severity in COVID-19 patients: Evaluation by laser Doppler perfusion monitoring and cytokine/chemokine analysis.

Letícia Sabioni, Andrea De Lorenzo, Cristiane Lamas, Fabiana Muccillo, Hugo Caire Castro-Faria-Neto, Vanessa Estato, Eduardo Tibirica

Abstract read
In one paragraph

Article in Microvascular research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Computational Prediction of the Interaction of Ivermectin with Fibrinogen.International journal of molecular sciences · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Therapeutic Approaches to the Neurologic Manifestations of COVID-19.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Letícia SabioniInstituto Nacional de Cardiologia, Ministério da Saúde, Rio de Janeiro, Brazil.
Andrea De LorenzoInstituto Nacional de Cardiologia, Ministério da Saúde, Rio de Janeiro, Brazil.
Cristiane LamasInstituto Nacional de Cardiologia, Ministério da Saúde, Rio de Janeiro, Brazil.
Fabiana MuccilloInstituto Nacional de Cardiologia, Ministério da Saúde, Rio de Janeiro, Brazil.
Hugo Caire Castro-Faria-NetoLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Vanessa EstatoLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro, Brazil.
Eduardo TibiricaInstituto Nacional de Cardiologia, Ministério da Saúde, Rio de Janeiro, Brazil. Electronic address: etibi@uol.com.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicrovascular dysfunction, serum cytokines and chemokines may play important roles in pathophysiology of coronavirus disease 2019 (COVID-19), especially in severe cases.

methodsPatients with COVID-19 underwent non-invasive evaluation of systemic endothelium-dependent microvascular reactivity - using laser Doppler perfusion monitoring in the skin of the forearm - coupled to local thermal hyperemia. Maximal microvascular vasodilatation (44 °C thermal plateau phase) was used as endpoint. A multiplex biometric immunoassay was used to assess a panel of 48 serum cytokines and chemokines. Severe COVID-19 (S-COVID) was defined according to WHO criteria, while all other cases of COVID-19 were considered mild to moderate (M-COVID). A group of healthy individuals who tested negative for SARS-CoV-2 served as a control group and was also evaluated with LDPM.

resultsThirty-two patients with COVID-19 (25% S-COVID) and 14 controls were included. Basal microvascular flow was similar between M-COVID and controls (P = 0.69) but was higher in S-COVID than in controls (P = 0.005) and M-COVID patients (P = 0.01). The peak microvascular vasodilator response was markedly decreased in both patient groups (M-COVID, P = 0.001; S-COVID, P < 0.0001) compared to the healthy group. The percent increases in microvascular flow were markedly reduced in both patient groups (M-COVID, P < 0.0001; S-COVID, P < 0.0001) compared to controls. Patients with S-COVID had markedly higher concentrations of dissimilar proinflammatory cytokines and chemokines, compared to patients with M-COVID.

conclusionsIn patients with COVID-19, especially with S-COVID, endothelium-dependent microvascular vasodilator responses are reduced, while serum cytokines and chemokines involved in the regulation of vascular function and inflammation are increased.

Indexed as

MicrocirculationAdultAgedChemokinesCOVID-19CytokinesEndothelium, VascularFemaleHealthy VolunteersHemodynamicsHumansImmunoassayLaser-Doppler FlowmetryMaleMiddle AgedPerfusionChemokinesCytokinesCOVID-19Endothelial dysfunctionLaser Doppler perfusion monitoringProinflammatory cytokines

Identifiers

PMID33278457
PMCPMC7710468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.